Cardiotoxicity

Cardiotoxicity assessments focus on determining adverse effects on the cardiovascular system caused by new chemical entities or therapeutic interventions.

Integrating cardiotoxicity early in the pipeline helps mitigate risks, ensuring the safety and efficacy of potential therapeutics.

Our scientific team and our network of specialist service providers can help you design the most appropriate biochemical and cellular assays using iPSC-derived cardiomyocytes to mitigate risk:

• Viability Assays: MTT, ATP-based assays, or LDH release for general cytotoxicity.

• Oxidative Stress Markers: ROS detection, lipid peroxidation, or antioxidant levels.

• Mitochondrial toxicity: mitochondrial resazurin metabolism

• Apoptosis/Necrosis: Annexin V/PI staining, caspase activation assays.

We offer a comprehensive range of instrumentation and cellular systems to help design the most appropriate assay, ensuring alignment with experimental goals and the generation of meaningful data.